<DOC>
	<DOCNO>NCT01359566</DOCNO>
	<brief_summary>To evaluate efficacy three dos XP19986 ( arbaclofen placarbil ) compare placebo treatment spasticity subject multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Efficacy Safety Arbaclofen Placarbil Subjects With Spasticity Due Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>1 . Has multiple sclerosis ( MS ) base Poser McDonald Criteria ( subtypes MS accept , include relapse remitting , primary secondary progressive , disease stable per exclusion criterion ) . 2 . Maximum Ashworth Score Scale score ≥ 2 least one follow muscle group either side body : hip abductors/adductors , knee flexors/extensors , ankle flexors/extensors . 3 . Expanded Disability Status Scale ( EDSS ) rating 3.08.0 inclusive . 4 . If subject disease modify MS treatment , dosage , frequency , route administration must stable least 30 day screen expect stable throughout study . 5 . Spasticity Disability Rating 2 high Baseline . 6 . Willing discontinue refrain use duration study drug treatment spasticity likely affect spasticity ( include , limited , baclofen , tizanidine , diazepam , clonazepam , metaxalone , dantrolene , cyclobenzaprine , carisoprodol , clonidine , vigabatrin , valproic acid cannabis ) . 1 . Spasticity due neurological disorder MS condition may confound assessment spasticity . 2 . Subject clinically evident muscle contracture result irreversible spasticity low extremity . 3 . Subjects suffer acute relapse MS ( determine Investigator ) within 90 day prior Screening , 1 relapse within year prior Screening 4 . Botulinum toxin injection within 6 month Screening current residual associate side effect Screening . 5 . Subjects receive concomitant medication one follow three drug class : ( Antiepileptic drug , Tricyclic antidepressants Opioids ) 6 . Subjects follow medication , dos specify limit , exclude maintain level within limit Gabapentin ≤ 1800 mg per day pregabalin ≤ 150 mg per day Amitriptyline ≤ 75 mg per day nortriptyline ≤ 75 mg per day Opioids ≤ 30 mg morphine equivalent per day . 7 . Evidence unstable severe systemic illness , include limited : Cardiovascular disease ( e.g. , chronic ventricular arrhythmia , unstable angina CHF ) , respiratory disease ( e.g. , sleep apnea , COPD require oxygen therapy hospitalization last year ) , endocrine disease , hepatic disease ( e.g. , chronic active hepatitis ) , renal disease , immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>